WHO Drug Information Vol. 25, No. 2, 2011

More documents

Recommendations

Info

Proposed INN: List 105 WHO Drug Information Vol. 25, No. 2, 2011pimasertibumpimasertibpimasertibpimasertibN-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]pyridine-4-carboxamideantineoplasticN-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophényl)amino]pyridine-4-carboxamideantinéoplasiqueN-[(2S)-2,3-dihidroxipropil]-3-[(2-fluoro-4-iodofenil)amino]piridina-4-carboxamidaantineoplásicoC 15 H 15 FIN 3 O 3 1236699-92-5NFIHOH OHNHONHrecoflavonumrecoflavonerécoflavonerecoflavona{[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4H-chromen-7-yl]oxy}acetic acidmucin production enhanceracide {[2-(3,4-diméthoxyphényl)-5-méthoxy-4-oxo-4H-chromen-7-yl]oxy}acétiqueamplificateur de production de mucineácido {[2-(3,4-dimetoxifenil)-5-metoxi-4-oxo-4H-cromen-7-il]oxi}acéticoestimulante de la secreción de mucinaC 20 H 18 O 8 203191-10-0OCH 3OCH 3HO 2 COOO OCH 3rucaparibumrucaparibrucaparib8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-oneantineoplastic8-fluoro-2-{4-[(méthylamino)méthyl]phényl}-1,3,4,5-tétrahydro-6H-pyrrolo[4,3,2-ef][2]benzazépin-6-oneantinéoplasique190
WHO Drug Information Vol. 25, No. 2, 2011 Proposed INN: List 105rucaparib8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6H-pirrolo[4,3,2-ef][2]benzazepin-6-onaantineoplásicoC 19 H 18 FN 3 O 283173-50-2FHNHN CH 3ONHsafotibantumsafotibantsafotibantsafotibantN-{[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl}-2-{2-[(4-methoxy-2,6-dimethylbenzenesulfonyl)(methyl)amino]ethoxy}-N-methylacetamidebradykinin receptor antagonistN-{[4-(4,5-dihydro-1H-imidazol-2-yl)phényl]méthyl}-2-{2-[(4-méthoxy-2,6-diméthylbenzènesulfonyl)(méthyl)amino]éthoxy}-N-méthylacétamideantagoniste des récepteurs de la bradykinineN-{[4-(4,5-dihidro-1H-imidazol-2-il)fenil]metil}-2-{2-[(4-metoxi-2,6-dimetilbencenosulfonil)(metil)amino]etoxi}-N-metilacetamidoantagonista de los receptores de bradiquininaC 25 H 34 N 4 O 5 S 633698-99-4NH 3 COCH 3CH 3NSCH 3 O OOOCH 3NNHselepressinumselepressinsélépressineselepresinavasopressin type 1a (V1a) receptor agonist;[2-L-phenylalanine,3-L-isoleucine,4-(6-oxo-L-lysine),8-[5-N-(propan-2-yl)-L-ornithine]]human vasopressinvasoconstrictoragoniste du récepteur de la vasopressine type 1a (V1a);[2-L-phénylalanine,3-L-isoleucine,4-(6-oxo-L-lysine),8-[5-N-(propan-2-yl)-L-ornithine]]vasopressine humainevasoconstricteuragonista del receptor de la vasopresina tipo 1a (V1a);[2-L-fenillalanina,3-L-isoleucina,4-(6-oxo-L-lisina),8-[5-N-(propan-2-il)-L-ornitina]]vasopresina humanavasoconstrictor191
Page 1 and 2:
WHO Drug Information Vol. 25, No. 2
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42: WHO Drug Information Vol. 25, No. 2
Page 91: WHO Drug Information Vol. 25, No. 2
show all

WHO Drug Information Vol. 25, No. 2, 2011

Create successful ePaper yourself

Delete template?

Save as template?